RafatAbonourMD

Hematology • Indianapolis, IN

Hematologic Oncology

Professor of medicine

Join to view full profile

Dr. Abonour is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Abonour's full profile

Already have an account?

Office
1044 W Walnut St
Rm 202
Indianapolis, IN 46202
Phone+1 317-274-0843

Fax+1 317-944-3349

Summary

Dr. Rafat Abonour is a hematologist in Indianapolis, IN and is affiliated with multiple hospitals in the area, including Select Specialty Hospital of INpolis, Eskenazi Health, Indiana University Health University Hospital, and Indiana University Health North Hospital. He received his medical degree from Damascus University Faculty of Medicine and has been in practice 32 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, and multiple myeloma.

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1992 - 1994
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1991 - 1992
Aurora Health CareResidency, Internal Medicine, 1989 - 1991
Damascus University Faculty of MedicineClass of 1984

Certifications & Licensure

IN State Medical License 1995 - 2025
WI State Medical License 1990 - 2013
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Indianapolis Monthly Castle Connolly, 2011, 2013

Clinical Trials

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency Start of enrollment: 2012 Jan 01
Completed
Phase 2
Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery Start of enrollment: 2018 Nov 08
Active, not recruiting
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) Start of enrollment: 2021 Apr 20
Terminated
Phase 1, Phase 2
The Indiana Myeloma Registry Start of enrollment: 2018 Jun 18
Recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

177 citations
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
Don M. Benson, Craig C. Hofmeister, Swaminathan Padmanabhan, Attaya Suvannasankha, Sundar Jagannath
Blood. 2012-11-22
86 citations
In Vivo DPP-4 Inhibition to Enhance Engraftment of Single-Unit Cord Blood Transplants in Adults with Hematological Malignancies
Sherif S. Farag, Shivani Srivastava, Steven Messina-Graham, Jennifer E. Schwartz, Michael J. Robertson
Stem Cells and Development. 2013-04-01
724 citations
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label random...
S. Vincent Rajkumar, Susanna Jacobus, Natalie S. Callander, Rafael Fonseca, David H. Vesole
The Lancet. Oncology. 2010-01-01

Abstracts/Posters

A Highly Robust Model for Predicting Outcome of Multiple Myeloma Patients By Inferring Patient-Specific Transcription Factor Activity
Rafat Abonour, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect¬ MM R...
Rafat Abonour, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect¬ MM Registry
Rafat Abonour, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: ...
Rafat Abonour, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Development of a Novel Deep Transfer Learning Framework to Characterize Inter- and Intra-Tumor Heterogeneity in Myeloma Patients
Rafat Abonour, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
Rafat Abonour, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
Rafat Abonour, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all